Rigel Pharmaceuticals, Inc.
RIGL institutional ownership changes in Q2 2026: 44 institutions opened or added positions, 50 trimmed or exited. RIGL (Rigel Pharmaceuticals, Inc.) is held by 93 institutional investors as of Q2 2026. Top institutional shareholders: BlackRock, Inc. ($75.9M), State Street Corp. ($40.7M), Vanguard Capital Management LLC ($30.7M). Institutions were selling, on balance.
Who's Trading
Latest move
Source dates: Price Nov 6, 2026 · Insiders Sep 3, 2026 · Activists Aug 14, 2026 · Congress none
Top Holders
| Action | ||||||
|---|---|---|---|---|---|---|
Increased | 1.9M(+9.7%) | $75.9M | 0.0% | +103.94% | 33 | |
Decreased | 1M(-7.2%) | $40.7M | 0.0% | +45.01% | 0 | |
Increased | 785,107(+2.7%) | $30.7M | 0.0% | +44.91% | 30 | |
Increased | 741,718(+36.2%) | $29M | 0.0% | +11.16% | 37 | |
Increased | 542,539(+21.7%) | $21.2M | 0.0% | +18.87% | 34 | |
Increased | 483,175(+9.7%) | $18.9M | 0.0% | +214.82% | 31 | |
Decreased | 367,393(-38.6%) | $14.4M | 0.0% | +75.50% | 0 | |
Increased | 233,728(+58.4%) | $9.1M | 0.0% | +25.89% | 39 | |
Decreased | 227,951(-39.9%) | $8.9M | 0.0% | +47.87% | 0 | |
Decreased | 226,780(-48.4%) | $8.9M | 0.0% | +53.75% | 0 | |
Decreased | 207,578(-48.9%) | $8.1M | 0.0% | +37.89% | 0 | |
New | 195,000 | $7.6M | 0.0% | +1.35% | 38 | |
Increased | 186,049(+88.2%) | $7.3M | 0.0% | +56.86% | 43 | |
Decreased | 154,627(-12.6%) | $6M | 0.0% | +85.38% | 0 | |
Increased | 146,381(+8.8%) | $5.7M | 0.0% | +234.25% | 30 | |
Decreased | 145,846(-56.9%) | $5.7M | 0.0% | +67.80% | 0 | |
Increased | 131,177(+4.4%) | $5.1M | 0.0% | +1.21% | 28 | |
Increased | 124,801(+37.1%) | $4.9M | 0.0% | +11.12% | 35 | |
Decreased | 123,961(-63.3%) | $4.8M | 0.0% | +31.05% | 0 | |
Decreased | 123,506(-14.3%) | $4.8M | 0.0% | +50.04% | 0 |
Showing 1-20 of 105
| Insider | Trade | Traded |
|---|---|---|
| Schorno Dean L | Exercise 1K sh | |
| Schorno Dean L | Exercise 694 sh | |
| Schorno Dean L | Exercise 620 sh | |
| Schorno Dean L | Exercise 2K sh | |
| Santos David A | Tax 874 sh | |
| Furey Raymond J. | Tax 877 sh | |
| RODRIGUEZ RAUL R | Tax 2K sh | |
| Schorno Dean L | Tax 928 sh | |
| HANNAH ALISON L. | Vest 24K sh | |
| MOOS WALTER H | Vest 6K sh |
| Filer | Stake | Filed |
|---|---|---|
| Armistice Capital, LLC | 8.9% | |
| Soleus Capital Master Fund, L.P. | 9.9% | |
| Armistice Capital, LLC | 6.9% | |
| Soleus Capital Master Fund, L.P. | 5.2% | |
| The Vanguard Group | 0.0% | |
| STATE STREET CORPORATION | 6.0% | |
| Morgan Stanley | 0.7% | |
| BlackRock, Inc. | 7.7% |
RIGLRigel Pharmaceuticals, Inc.Continue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Incorporated
LLYEli Lilly and Company
TMOThermo Fisher Scientific Inc
JNJJohnson & Johnson
DHRDanaher Corporation
ISRGIntuitive Surgical, Inc.
MRKMerck & Company, Inc.
ABBVAbbVie Inc.
BSXBoston Scientific Corporation
ABTAbbott LaboratoriesQuestions investors ask about RIGL
Who owns RIGL?
93 institutional investors held RIGL on June 30, 2026, led by BlackRock, Inc. ($75.9M), State Street Corp. ($40.7M) and Vanguard Capital Management LLC ($30.7M).
How many hedge funds hold RIGL?
93 institutional investors reported RIGL in their 13F filings for the quarter ended June 30, 2026, $406.9M in all. 4 of them are rated Elite.
Are institutions buying or selling RIGL?
Selling, on balance. In Q2 2026, 50 institutions trimmed or exited RIGL and 44 institutions opened or added to positions.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer